Reviewing ConforMIS (CFMS) and Its Peers
ConforMIS (NASDAQ: CFMS) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its competitors? We will compare ConforMIS to related companies based on the strength of its earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.
This is a breakdown of current recommendations and price targets for ConforMIS and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ConforMIS currently has a consensus target price of $6.13, indicating a potential upside of 102.81%. As a group, “Medical Devices & Implants” companies have a potential upside of 37.66%. Given ConforMIS’s higher probable upside, analysts plainly believe ConforMIS is more favorable than its competitors.
This table compares ConforMIS and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
36.0% of ConforMIS shares are held by institutional investors. Comparatively, 54.9% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 9.6% of ConforMIS shares are held by insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares ConforMIS and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|ConforMIS||$79.90 million||-$57.58 million||-2.25|
|ConforMIS Competitors||$1.67 billion||$207.58 million||76.15|
ConforMIS’s competitors have higher revenue and earnings than ConforMIS. ConforMIS is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
ConforMIS has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500. Comparatively, ConforMIS’s competitors have a beta of 0.94, indicating that their average share price is 6% less volatile than the S&P 500.
ConforMIS competitors beat ConforMIS on 8 of the 12 factors compared.
ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints. It offers a line of customized knee implants designed to restore the natural shape of a patient’s knee. It offers iTotal CR, which is a total knee replacement implant. Its iFit technology platform consists of three elements, including iFit Design, its algorithms and computer software that is used to design customized implants and associated single-use patient-specific instrumentation referred to as iJigs, based on computed tomography scans of the patient and to prepare a surgical plan customized for the patient (iView); iFit Printing, which is a three-dimensional printing technology used to manufacture iJigs, and iFit Just-in-Time manufacturing and delivery capabilities.
Receive News & Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.